Related Experiment Video
Updated: Jun 1, 2026
14:58
Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
Should we reoperate for recurrent high-grade astrocytoma?
Jin-fang Xu1, Jun Fang, Yi Shen
1Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou City, 310009, People's Republic of China.
Journal of Neuro-Oncology
|May 19, 2011
Summary
Reoperation for recurrent high-grade astrocytoma significantly improves survival time and quality of life. This study found that patients undergoing reoperation lived longer and had better progression-free survival compared to those who did not have reoperation.
Area of Science:
- Neuro-oncology
- Neurosurgery
- Clinical Oncology
Background:
- High-grade astrocytoma frequently recurs despite optimal initial treatment.
- The benefit of reoperation for recurrent astrocytoma remains debated.
- Objective evaluation of reoperation's efficacy is needed.
Purpose of the Study:
- To investigate the therapeutic effect of reoperation in recurrent high-grade astrocytoma.
- To compare survival outcomes between patients with and without reoperation.
Main Methods:
- Retrospective case-matched study of 63 recurrent high-grade astrocytoma patients (2006-2008).
- 21 patients underwent reoperation; 42 matched controls did not.
- Matching criteria included demographics, KPS, histopathology, recurrence interval, initial surgery extent, adjuvant treatment, and tumor characteristics.
Main Results:
- Median survival time was 7 months with reoperation vs. 4 months without (P < 0.001).
- Median progression-free survival (PFS) was 5 months with reoperation vs. 2.5 months without (P < 0.001).
- Reoperation, KPS score, and tumor location were significant prognostic factors.
Conclusions:
- Reoperation is a beneficial treatment for recurrent high-grade astrocytoma.
- Reoperation can prolong survival and improve quality of survival.
- Further research into surgical indications for recurrent astrocytoma is warranted.
